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Abstract 
 Parents of young children with type 1 diabetes (T1D) experience unique, developmental 
challenges in managing their child’s T1D, resulting in psychosocial distress.  Only a small 
portion of young children reach glucose goals and adherence to diabetes devices that help 
improve T1D management have historically been low in this population. The purpose of this 
study is to test four interventions that couple developmentally tailored behavioral supports with 
education to optimize use of diabetes devices and reduce psychosocial distress for parents of 
young children with T1D. The study team designed four behavioral interventions, two aimed at 
improving glucose control and two aimed at optimizing use of diabetes devices.  The goal of this 
paper is to describe the behavioral interventions developed for this study, including the results of 
a pilot test, and describe the methods and analysis plan to test this intervention strategy with 
ninety participants in a large-scale, randomized trial using a SMART design.  A SMART design 
will permit a clinically relevant evaluation of the intervention strategy, as it allows multiple 
randomizations based on individualized assessments throughout the study instead of a fixed 
intervention dose seen in most traditional randomized controlled trials. 
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1. Introduction 
Type 1 diabetes (T1D) is a common chronic medical condition in childhood, affecting 1 in 
400 youth in the U.S. under the age of 20 (1), many of whom are diagnosed with T1D at a very 
young age (i.e. < 6 years old)(2).  According to recent data from a large diabetes registry, only 
23% of children ages 2-5 years old meet glucose targets set by the American Diabetes 
Association (i.e., A1C <7.5%) (3), despite technological advances in insulin pumps and 
continuous glucose monitoring (CGM) that permit precision and flexibility in insulin dosing and 
rapid detection of glucose fluctuations.  However, regular use (i.e., adherence) of CGM therapy 
has been low in young children (4-6).  Therefore, the purpose of the current study was to test 
strategies to improve T1D management in young children by optimizing use of diabetes 
technologies to improve T1D health outcomes. 
Young children with T1D have unique challenges for T1D management resulting in 
significant psychosocial burden for parents (7, 8).  Young children have unpredictable eating 
habits, making precise meal-time insulin dosing difficult and they often have erratic activity 
patterns causing greater glycemic variability (9).  In addition, young children are unable to 
recognize and articulate symptoms of hypo- and hyperglycemia often resulting in parental hyper-
vigilance to detect and correct glycemic excursions in their children. Hypoglycemia can cause 
seizures and parents often awaken several times per night to check their child’s glucose levels (7, 
10, 11).  During the day, parents must rely on other, often inexperienced caregivers, such as 
school or daycare personnel, to manage their child’s T1D, which is an additional source of stress 
and worry (12).  Parents of young children are often fearful of hypoglycemia and are at greater 
risk for depression and anxiety compared to parents of older children with T1D (13).  Parents 
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who are fearful of hypoglycemia may maintain high blood glucose in their young children to 
allay their worries about hypoglycemia (14).  
Despite the unique developmental and psychosocial challenges that may negatively influence 
glucose control in young children with T1D, there is limited research on behavioral interventions 
to address T1D management challenges while addressing the psychosocial needs of parents (7).  
Further, there are no interventions to improve the use of diabetes technologies in young children 
and their parents.  Therefore, we designed a study to test an intervention targeting parents of 
young children with T1D that couples developmentally tailored behavioral supports with 
education to optimize use of CGM to improve glycemic control and reduce the psychosocial 
burdens of T1D management.  The purpose of this paper is to: 1) describe the behavioral 
interventions developed for this study, including the results of a pilot study; and 2) describe the 
methods and analysis plan for a large scale, adaptive randomized clinical trial using a sequential 
multiple assignment randomized trial (SMART) design. 
2.  Behavioral interventions and pilot study 
The first step in designing this clinical trial was to create behavioral interventions designed to 
increase adherence to diabetes devices and improve glucose control for young children with 
T1D.  After intervention development was complete, a pilot study was conducted to gain 
experience implementing the interventions and to test and refine the interventions in preparation 
for the main trial.  An additional goal of the pilot study was to assess the feasibility of delivering 
the behavioral interventions remotely, via web-based conference software with video capability. 
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2.1 Behavioral interventions 
A multidisciplinary team of pediatric endocrinologists, psychologists, nurses, and certified 
diabetes educators collaborated to develop four behavioral interventions to address low 
adherence to CGM and suboptimal glucose control.  Intervention content was derived from the 
clinical experience of the research team in addition to a review of the scientific literature.  
Specifically, the goals of the four interventions were to: 1) provide technical education on device 
use and age-appropriate strategies for improving glycemic control; 2) reduce distress and fear of 
hypoglycemia; and 3) teach problem-solving skills to overcome barriers to device use. Distress 
Reduction and Developmental Demands interventions were designed to increase adherence to 
CGM, referred to as the ‘Optimize Adherence’ interventions.  Fear of Hypoglycemia and Dual 
Wave interventions were designed to improve blood glucose control, referred to as the ‘Glucose 
Target’ interventions. 
Optimize Adherence Interventions 
The Developmental Demands intervention focused on increasing parents’ comfort with 
using technology with their young children. In session 1, Technical aspects of using CGM were 
reviewed as well as benefits of diabetes technology, including remote monitoring of glucose 
levels and trends while the child was out of parental care (e.g., at school, with another relative or 
caregiver). Parents were taught problem-solving skills to identify barriers to optimal utilization 
of diabetes technology with their young children and to develop age-appropriate solutions to 
overcome these barriers.  Common barriers to technology use included insurance coverage, 
struggles to keep devices attached to the child, handling questions from others about the devices, 
training other caregivers to use the technology, and feeling anxious that the technology might 
fail.  In session 2, progress since the last session was discussed, and parents were again engaged 
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in problem solving to develop solutions to both previously identified and newly identified 
barriers.   Parents were provided with the opportunity to role-play solutions to identified barriers, 
and to discuss potential barriers that could develop in the future.  Finally, parents were provided 
with suggestions for resources if problems overcoming barriers should arise in the future.   
The Distress Reduction intervention focused on reducing parental stress related to their 
child’s T1D and other parenting stressors.  Emphasis was placed on identification of worries and 
sources of stress, as well as utilization of stress reduction strategies such as problem- solving, use 
of balanced/reality-based self-talk, relaxation exercises, and obtaining social support.  The 
interventionist provided global psychoeducation and support and tailored the intervention to 
specific areas of distress raised by parents. In session 1, interventionists assisted parents to 
identify their most prominent fears, worries, and sources of distress related to their child’s T1D, 
and discussed strategies for stress management.  Interventionists educated parents on the stress 
management strategies and encouraged parents to practice these before the next session.  In 
session 2, progress since the last session was reviewed, and the parents were guided in discussion 
of whether additional strategies were needed to address already identified worries and sources of 
stress, or if new worries or sources of stress had emerged.  Parents were provided with the 
opportunity to practice skills and/or role-play scenarios as appropriate.   Finally, interventionists 
assisted parents in problems solving any barriers that arose in implementing strategies to reduce 
worry and distress.    
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Glucose Target Interventions 
Maintaining high blood glucose levels is a common response to worries about 
hypoglycemia and may include behaviors such as treating hypoglycemia with too many 
carbohydrates (i.e., over treating hypoglycemia), under-dosing insulin to maintain a higher than 
recommended blood glucose level, or initiating hypoglycemia treatment when glucose levels are 
above the hypoglycemic range (i.e., 70 mg/dl).  The Fear of Hypoglycemia intervention 
incorporated principles of exposure-based cognitive behavioral therapy into hypoglycemia 
management (15) and reinforced appropriate hypoglycemia treatment and prevention strategies. 
The interventionist guided parents to gradually reduce blood glucose levels to the medically 
recommended range, with blood glucose monitoring prior to meals, at bedtime and as needed for 
symptoms of hypo or hyperglycemia, along with anxiety management strategies.    
The Dual Wave intervention focused on reducing post-meal hyperglycemia by using the 
dual wave bolus feature of the insulin pump, when parents were unsure of what their child would 
eat. A dual wave bolus provides a portion of the meal bolus as a standard bolus at the time of the 
meal, and extends a second portion of the meal bolus for a variable numbers of hours, as 
programmed by the user (usually 1-3 hours). Parents were guided to calculate the immediate 
portion of the dual wave bolus based on the minimum number of carbohydrates they confident 
their child would eat, and to extend the remaining amount of insulin to cover the rest of the 
carbohydrates in the planned meal as the extended portion of the bolus.  The extended portion of 
the bolus could be cancelled if the child failed to eat their entire meal. Session 1 focused on 
education regarding these procedures as well as answering any questions from parents. Session 2 
focused on refining parents’ techniques after they had some experience utilizing the approach. 
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2.2. Pilot study 
Participants and pilot study design 
Nineteen parents of children < 6 years old using both CGM and insulin pumps for T1D 
management enrolled in a 6-week, pilot feasibility study to test and refine the interventions in 
preparation for the larger, randomized clinical trial.  The children of the participating parents 
were 4.2 + 1.3 years of age (range= 1.6 – 5.9 yrs of age) and had type 1 diabetes for an average 
of 2.3 + 1.0 years (range= 0.6-4.8 yrs).  Fifty-three percent of children had been using insulin 
pumps to manage T1D for > 1 year and 42% had been using CGM for > 1 year.  The remaining 
participants used insulin pumps and CGM for < 1 year.  One parent withdrew from the study 
prior to completing any interventions, resulting in a final sample size of 18 parents.  The study 
took place at the University of Colorado Barbara Davis Center, Stanford University, and Indiana 
University, and IRB approval was obtained at each study site.  Stanford served as the 
coordinating center for devices and data management. Informed consent was obtained from 
parent participants. 
Nine families were assigned to complete the ‘Optimizing Adherence’ interventions 
(consisting of Developmental Demands and Distress Reduction) and nine families were assigned 
to complete the ‘Glucose Control’ interventions (consisting of the Fear of Hypoglycemia and 
Dual Wave).  Each intervention consisted of two, 60-90 minute sessions with a certified diabetes 
educator, physician, or psychologist completed 1 week apart, for a total of four intervention 
sessions completed in a 4-6 week period.  Interventionists followed an intervention guide to 
ensure the delivery of all intervention components.  All intervention sessions were completed 
remotely from the participants’ home, via web-based, HIPPA-secure video conferencing 
software (e.g. Blue Jeans, Vidyo or Google Hangouts).    
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Measures 
Participants completed three questionnaires at the beginning and end of the pilot study: 1) 
Hypoglycemia Fear Survey- worry subscale (16), a self-report measure of worry related to 
hypoglycemia and its negative consequences; 2) Diabetes Distress scale (17), a self-report 
measure of emotional distress related to diabetes and its management; and 3) the CGM 
satisfaction scale, which is a self-report measure of treatment satisfaction with continuous 
glucose monitoring (18).  To evaluate the impact on glycemic outcomes, parents downloaded 
their child’s CGM 1 week prior to the first intervention session and again 1 week after 
completing all assigned intervention sessions to calculate the percent time sensor glucose values 
were in target range (70-180 mg/dl).   
Results 
Sixteen of the 18 families completed at least 3 of the 4 intervention sessions (89%).  
There were minimal technical difficulties, parents, and interventionists found the web-based 
program convenient and easy to use.  Paired t-tests showed a statistically significant decrease in 
fear of hypoglycemia scores and a significant increase in CGM satisfaction for the 16 families 
who completed at least 3 intervention sessions (p=0.04 for both), with moderate effect sizes 
(Cohen’s d=0.59 and 0.55 respectively).  A decrease in diabetes distress scores was also 
observed, however, the effect size was small (Cohen’s d=0.32) and it was not statistically 
significant (p= 0.23).  Analyzable CGM data were available for 10 of the 16 completing families.  
Typically, children in this age group have sensor values within target range (70-180 mg/dl) 40-
50% of the time (19).  In this study, we observed a 9% increase in glucose time in range, from 
45% at study enrollment to 54% following the interventions.  Data were missing from six 
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participants due to parents’ not uploading CGM data as requested or errors in the uploaded CGM 
files making calculation of percent time in target range impossible (table 1).   
Summary of Pilot Results 
  The high completion rate and positive feedback from interventionists confirmed that 
completing the interventions remotely was effective.  The pilot results from this small sample 
population suggest that the interventions have potential to improve some psychosocial aspects of 
care, including reducing fear of hypoglycemia, increasing satisfaction with CGM, and increasing 
sensor glucose time in target range. The interventions had minimal impact on diabetes distress, 
which could be due to the short duration of the pilot and that diabetes distress is a global stressor 
related to many facets of diabetes, not just technology use.  It was difficult to get all participants 
to complete uploads of their CGM devices at home.  Therefore, we chose to use a cloud-based 
system that did not require parents to upload the CGM device, to collect glucose data for the 
larger scale, clinical trial and reduce the incidence of missing data.  
2.3 Intervention Refinement 
The behavioral interventions were refined based on the pilot study results and feedback 
from study participants and interventionists.  For the larger adaptive, randomized clinical trial, 
interventions were also refined to be specific to CGM use, which permitted enrollment of 
participants using multiple daily injections (MDI) or insulin pump therapy.  The primary change 
made to the interventions following the pilot study was to replace the ‘Dual Wave’ intervention, 
which was only applicable to insulin pump users, with a ‘Remote Monitoring’ intervention, 
specific to CGM use. 
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The Remote Monitoring intervention focused on using the remote monitoring feature on 
the Dexcom G5 CGM system (i.e. ‘Share’), the device used in this study, which allows parents to 
view their child’s glucose data directly on their smart phone, even when they are away from their 
child.  Thus, the Remote Monitoring intervention also focused on overcoming challenges to 
remotely monitoring their child’s glucose levels, in addition to strategies to use remote 
monitoring to reduce worries about hypoglycemia, increase safety, and facilitate communication 
with other caregivers, including school personnel.  Finally, participants were also taught to 
identify patterns of high and low blood glucose by reviewing their child’s CGM data and making 
therapy adjustments in response to the identified patterns.  Only minor adjustments were made to 
the other three interventions. See Table 2 for a description of the final behavioral interventions 
used in the larger scale, adaptive, randomized clinical trial.  
  The main barriers to intervention completion were scheduling difficulties and time 
constraints.  Therefore, to reduce scheduling difficulties, intervention time was reduced from 60-
90 min to 45-60 min.  Additionally, more flexibility will be employed when scheduling 
intervention sessions (i.e., weekends, evenings) for the large-scale adaptive, randomized clinical 
trial.    
3.  Sequential multiple assignment randomization trial (SMART) methods 
3.1 Study Aims and Hypothesis 
The primary aim of the SMART design is to leverage CGM and behavioral supports for 
parents to improve glycemic and psychosocial outcomes. We hypothesize that the exposure to 
the interventions will increase the family’s adherence to CGM use (i.e., increase the number of 
days used during the week) and increase time in the target glucose range of 70-180mg/dl, our 
primary outcome.  Additionally, we hypothesize that exposure to the interventions will improve 
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psychosocial indicators of quality of life for parents of young children with type 1 diabetes, our 
secondary outcomes. 
3.2 SMART design rationale 
This study uses a SMART design, which is an adaptive study design that allows for 
multiple assessments and subsequent randomizations based on the result of each assessment.  A 
traditional randomized controlled trial, which tests the effect of a set intervention dose, does not 
align well with the reality of clinical practice where intervention strategies and dose are adapted 
based on individual patient needs and response to intervention (20, 21).  Typically, in T1D 
clinical practice, a patient begins using a diabetes management device with an initial dose of 
education and if problems arise, the clinical team offers further assistance (which may include 
more education, help with problem-solving challenges, etc.) to optimize use of the device.  A 
SMART design allows for the testing of the multiple intervention strategies developed for this 
trial (Table 2), which are employed based on individual patient outcomes and response to 
previous interventions during the course of the study.  This approach tests which interventions 
are best to address the unique challenges parents of young children experience in using diabetes 
devices and achieving glucose targets.   
3.3 SMART Trial Study Design 
Participants 
 Ninety parents with children 2- 6 years old with T1D for > 6 months will be recruited 
from four academic clinical centers that specialize in pediatric T1D care: University of Colorado 
Barbara Davis Center for Diabetes, Stanford University, Indiana University, and University of 
South Florida.  Children using CGM must have an A1C >7.5% to be eligible for enrollment.  If 
children are not current CGM users, there is no A1C eligibility requirement.  All children will 
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use the Dexcom G5 CGM system with initial education that is consistent with practice standards 
for starting CGM systems.  
Study Procedures  
All caregivers will complete a “checkpoint” visit every 4 weeks while they are enrolled in 
the 6-month study.  The Dexcom G5 CGM system uses a mobile application that automatically 
uploads glucose data to the cloud when connected to Wi-Fi or cellular data, permitting easy 
access to CGM data for study staff.  At each monthly checkpoint, study staff will review the 
CGM data from the previous 4 weeks to assess for CGM adherence or glucose control targets.  
The CGM adherence target is sensor wear at least 6 of 7 days (on average) during a week; or < 4 
missed days in the previous 4 weeks.  The glucose target is sensor glucose values in the target 
range (70-180 mg/dl) at least 60% of the time.   
At each checkpoint, if the defined glucose and/or adherence targets is not met, a 
randomization occurs. For each randomization pathway (Optimize Adherence and Glucose 
Target), there are 3 conditions; 2 active interventions and 1 no-intervention/control.  
Randomization will occur by order and the sequence of interventions will depend on whether a 
previous intervention was completed (i.e., a participant can only be randomized to each 
intervention once).  Participants can receive a minimum of zero interventions or a maximum of 4 
interventions (a maximum of 2 Optimize Adherence interventions and 2 Glucose Target 
interventions) during the 6-month period.   
Figure 1 shows the randomization strategy that will be used in this study.  If the 
participant does not meet the adherence target, he/she will enter the adherence pathway and be 
randomized to 1 of 3 groups: 1) no intervention; 2) Developmental Demands; or 3) Distress 
Reduction.  If the participant does not meet the glucose target, he/she will enter the glucose 
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control pathway and be randomized to one of 3 groups: 1) no intervention; 2) Fear of 
Hypoglycemia; or 3) Remote Monitoring.  Finally, if a participant does not meet both the 
glucose and adherence targets at the same checkpoint, she/he will enter the adherence 
randomization pathway first. Using the CGM is critical to improving glucose control.  Therefore, 
CGM adherence interventions precede glucose control interventions in these cases. At each 
monthly checkpoint, if the participant meets both the glucose and adherence targets, no 
randomization occurs. 
Measures 
Data will be collected either remotely (via RedCap) or in clinic at baseline (week 0), at 
each monthly checkpoint visit (weeks 4, 8, 12, 16, 20) and at study completion (week 24).  
Demographic data, including socioeconomic status, racial and ethnic background, and diabetes 
device use history will be collected at study enrollment.  The two primary outcomes will be 
glycemic control and quality of life.  Glycemic control variables include change in time spent in 
target range (70-180 mg/dL) from baseline to study completion; and change in HbA1c.  
Psychosocial variables to assess quality of life include health related quality of life, parents’ 
general depression and anxiety symptoms, T1D-related distress, and hypoglycemia worries.  
T1D-related technology attitudes will also be assessed and include CGM satisfaction and 
comfort with use (See Table 3).  The time in target blood glucose range and adherence will be 
collected from CGM data, whereas psychosocial and T1D technology attitude variables will be 
collected via questionnaire completion via RedCap (22).  At baseline (week 0) and study 
completion (week 24) a capillary blood sample will be obtained to measure A1c.  If the 
participant has a clinic visit at 12 weeks (+/- 2 weeks), an A1c value will be captured from the 
electronic medical chart. At baseline (week 0) and study completion (week 24), parents complete 
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the full psychosocial assessment battery and at each monthly checkpoint visit, parents complete 
only select questionnaires.   
4. Statistical Analysis Plan 
After data integrity checks are completed and the data are determined to be complete, 
descriptive statistics will be carried out to characterize the sample and note baseline scores on 
glycemic and psychosocial measures as well as rates of meeting criteria for randomizations at 
each checkpoint. Our primary and secondary outcomes will be tested in two ways. First, by using 
latent growth curve models to compare change in response to treatment strategies, we can 
examine outcomes from checkpoint to checkpoint. For example, we can test percent change in 
time spent in range from month 2 to 3 and determine which intervention is associated with 
promotion of change during that time period. Because more than three time points are available 
in this study, nonlinear trajectories will also be examined. Second, we will also examine the 
treatment effect using separate individual trajectory models for both primary outcomes across the 
entire 6 months of the study. Following this examination, we will investigate moderators of the 
treatment effects to determine for whom the interventions are most or least effective by including 
the baseline measure in a three-way interaction with the treatment by time interaction terms 
within the individual trajectory models. These analyses will inform more precise sample size 
considerations based on observed effect sizes for a larger efficacy trial conducted after this 
research is completed. 
5. Discussion 
 Diabetes technologies, such as CGM, are valuable tools to improve glycemic control.  
However, individuals have to use the technology consistently to realize these benefits and they 
need sufficient education and support to optimize use.  This is especially true for parents of 
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young children with type 1 diabetes, who experience unique challenges in diabetes management 
related to their child’s developmental stage.  This trial aims to test a series of interventions that 
were strategically developed for this unique population and pilot tested.  
There is no “one-size fits all” approach to improving diabetes care for young children and 
their families.  The novel SMART design being used in this trial is more clinically relevant than 
a traditional randomized controlled trial, as it permits individualized assessment, similar to how a 
clinician would approach care.  Further, integration of psychosocial support with diabetes 
education is paramount to improving outcomes for this vulnerable population, and the  
interventions being tested here attempt to provide this holistic approach.  The results of this trial 
will add valuable knowledge to the field about what types of interventions may be most helpful 
in increasing use of CGM technology and improving glycemic control for young children with 
T1D. 
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Table 1.  Changes from pre- to post-intervention on parent measures for completing families in 
the pilot 
study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  mean (SD) mean comparisons 
Parent Measures N pre- post- t p Cohen’
s d 
Hypoglycemia fear 16 22.3 (7.3) 18.8 (5.2) 2.26 0.04 0.59 
Glucose monitoring 
satisfaction 
16 20.9 (3.2) 23.0 (3.1) 2.24 0.04 0.55 
Diabetes distress 16 25.3 (6.6) 23.9 (5.7) 1.26 0.23 0.32 
% time in range  10 45.2 (17.9) 53.7 (11.6) 1.75 0.11 0.60 
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Table 2: Description of the behavioral 
interventions developed for the main 
clinical trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each intervention consists of two, 45-60 minute sessions delivered over a two-week period.  
Interventions are delivered by a Certified Diabetes Educator (CDE), medical personnel or psychologist 
with advanced training and experience in T1D care with young children.  Distress Reduction intervention 
is delivered by a PhD psychologist with advanced training and experience in diabetes.  
 
 
 
 
 
 
 
Intervention 
Name 
Intervention Goal 
Developmental 
Demands 
Provide education on using 
diabetes technology in various 
settings and formats and 
increase problem-solving skills. 
Distress 
Reduction 
Identify and reduce parent 
distress and worries. Provide 
strategies for obtaining social 
support. 
Fear of 
Hypoglycemia 
Decrease fear of hypoglycemia 
by decreasing maladaptive 
cognitions and decreasing 
behaviors that maintain high 
blood glucose levels 
Remote 
Monitoring 
Optimize use of remote 
monitoring (i.e., Share) by 
focusing on situational 
demands and problem solving. 
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Figure 1: Randomization strategy at each monthly checkpoint 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adherence Target= sensor wear > 6 out of 7 days per week or < 4 missed days in the previous 4 weeks 
Glucose Target= sensor glucose values 70-180 mg/dl > 60% of time 
If participant does not meet the glucose target, randomization occurs to a glucose target intervention 
If participant does not meet the adherence target, randomization occurs to an optimize adherence     
intervention 
 
 
Meets Adherence & Glycemic Targets 
Does not meet Targets 
No intervention 
Developmental Demands intervention 
Reducing Distress intervention 
No intervention 
Fear of Hypoglycemia intervention 
Remote Monitoring intervention 
No intervention 
Optimize Adherence 
Glucose Target 
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Table 3: Psychosocial & T1D-Technology Attitudes Assessment Battery 
Measure Construct Items and 
Scoring 
Psychometric 
properties 
*Problem Areas in 
Diabetes, Parent 
Version (Paid-PR)  
Parental distress related to 
child’sT1D 
18 items 
 
 
α= 0.87 (23) 
*Patient Health 
Questionnaire (PHQ-
8)  
Depressive symptoms 8 items 
Prevalence of 
current 
depression if 
score ≥10 
Sensitivity=0.80 
Specificity=0.92 (24) 
[article is discussing 
PHQ9] 
*State-Trait Anxiety 
Inventory (STAI) 
 Anxiety symptoms.   40 items α= 0.86-0.95(25) 
Pittsburgh Sleep 
Quality Index 
(abbreviated) 
 Self-reported sleep quality 
and quantity.   
8 items α= 0.83(26) 
Hypoglycemic Fear 
Survey-Parents; 
worry subscale 
(HFS-P) 
Parents’ worry related to 
hypoglycemia 
18 items α= 0.89(16) 
 
   
Hypoglycemic 
Confidence 
Questionnaire 
(parent) 
Parents’ self-assurance in 
managing hypoglycemia. 
8 items α = 0.87(27) 
Pediatric Quality of 
Life Inventory 
(PedsQL)  
 Health related quality of 
life 
23 items α =0.90(28) 
T1D Technology Attitudes 
Measure Construct Items and 
Scoring 
Psychometric 
Properties 
Glucose Monitoring 
System Satisfaction 
Survey (GMSS-T1D) 
Self-report of treatment 
satisfaction with glucose 
monitoring devices and its 
impact on quality of life 
15 items α =0.90(18) 
Use and comfort with 
technology 
Objective questions 
capturing the frequency and 
variability of technology 
use for both general and 
22 items N/A 
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*indicates the questionnaire is completed at each monthly checkpoint visit in addition to baseline 
and study completion 
diabetes-specific devices.   
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